公开(公告)号：US20180016224A1

公开(公告)日：2018-01-18

申请号：US15498726

申请日：2017-04-27

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Hang ZHAO ,  Stefan G. KOENIG ,  Charles P. VANDENBOSSCHE ,  Surendra SINGH ,  Harold Scott WILKINSON ,  Roger P. BAKALE

IPC: C07C231/14 ,  C07C231/12 ,  C07B43/06 ,  C07C209/62 ,  C07C209/50 ,  C07C249/08 ,  C07C211/42

CPC classification number: C07C231/14 ,  C07B43/06 ,  C07C209/50 ,  C07C209/62 ,  C07C211/42 ,  C07C231/12 ,  C07C249/08 ,  C07C2602/10

Abstract: This invention provides a convenient method for converting oximes into enamides. The process does not require the use of metallic reagents. Accordingly, it produces the desired compounds without the concomitant production of a large volume of metallic waste. The enamides are useful precursors to amides and amines. The invention provides a process to convert a prochiral enamide into the corresponding chiral amide. In an exemplary process, a chiral amino center is introduced during hydrogenation through the use of a chiral hydrogenation catalyst. In selected embodiments, the invention provides methods of preparing amides and amines that include the 1,2,3,4-tetrahydro-N-alkyl-1-naphthalenamine or 1,2,3,4-tetrahydro-1-naphthalenamine sub structure.

公开(公告)号：US20240279171A1

公开(公告)日：2024-08-22

申请号：US18565618

申请日：2022-06-02

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Robert Joseph PRYTKO ,  John R. SNOONIAN ,  Harold Scott WILKINSON ,  Anna BALANOV

IPC: C07D207/09 ,  A61K31/40

CPC classification number: C07D207/09 ,  A61K31/40

Abstract: Provided are methods for making crystalline forms of (S)-(−)-amisulpride and (R)-(+)-amisulpride. Also provided are pharmaceutical compositions comprising the crystalline forms of (S)-(−)-amisulpride and (R)-(+)-amisulpride and methods of using the crystalline forms.

公开(公告)号：US20200290987A1

公开(公告)日：2020-09-17

申请号：US16817749

申请日：2020-03-13

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Nandkumar Nivritti BHOGLE ,  Takahiko HASHIZUKA ,  Robert Joseph PRYTKO ,  John R. SNOONIAN ,  Harold Scott WILKINSON ,  Haitao ZHANG

IPC: C07D311/76

Abstract: The present disclosure relates to salts of (R)-1-(8-fluoroisochroman-1-yl)-N-methylmethanamine, crystalline forms thereof, and methods of preparation thereof, which are useful in the treatment of CNS disorders.

公开(公告)号：US20220402937A1

公开(公告)日：2022-12-22

申请号：US17814378

申请日：2022-07-22

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Andrea BAUER ,  Nandkumar Nivritti BHOGLE ,  Xiaoxia CHEN ,  Shahla JAMZAD ,  Robert Joseph PRYTKO ,  Kostas SARANTEAS ,  Michael Joseph SIZENSKY ,  Harold Scott WILKINSON ,  Haitao ZHANG

IPC: C07D495/04 ,  A61P25/18 ,  A61K9/20 ,  A61K45/06 ,  A61K31/381 ,  A61P25/00

Abstract: Provided are salts of (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine and various of crystal forms thereof, and compositions, medicaments, pharmaceutically acceptable formulations thereof, and methods of making same. In addition, provided are compounds comprising specific particle size distributions of crystalline (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine HCl and methods of making and modulating the particle size distributions.

公开(公告)号：US20220098163A1

公开(公告)日：2022-03-31

申请号：US17347709

申请日：2021-06-15

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Nandkumar Nivritti BHOGLE ,  Takahiko HASHIZUKA ,  Robert Joseph PRYTKO ,  John R. SNOONIAN ,  Harold Scott WILKINSON ,  Haitao ZHANG

IPC: C07D311/76

Abstract: The present disclosure relates to salts of (R)-1-(8-fluoroisochroman-1-yl)-N-methylmethanamine, crystalline forms thereof, and methods of preparation thereof, which are useful in the treatment of CNS disorders.

公开(公告)号：US20210053983A1

公开(公告)日：2021-02-25

申请号：US17006101

申请日：2020-08-28

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Andrea BAUER ,  Nandkumar Nivritti BHOGLE ,  Xiaoxia CHEN ,  Shahla JAMZAD ,  Robert Joseph PRYTKO ,  Kostas SARANTEAS ,  Michael Joseph SIZENSKY ,  Harold Scott WILKINSON ,  Haitao ZHANG

IPC: C07D495/04 ,  A61P25/18 ,  A61K9/20 ,  A61K45/06 ,  A61K31/381 ,  A61P25/00

Abstract: Provided are salts of (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine and various of crystal forms thereof, and compositions, medicaments, pharmaceutically acceptable formulations thereof, and methods of making same. In addition, provided are compounds comprising specific particle size distributions of crystalline (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine HCl and methods of making and modulating the particle size distributions.